BioTrinity 2024
Physiomics plc (AIM: PYC), a leading mathematical modelling and data science company supporting the development of new therapeutics and personalised medicine solutions, is pleased to announce that it is attending BioTrinity 2024, OBN’s leading life sciences conference, in London on 23rd and 24th of April 2024.
Physiomics’ Head of Business Development, Hayley Close will be attending the event which aims to catalyse growth in the life sciences industry and is attended by 600+ experts from the field. Physiomics’ objective is to meet with leaders of early-stage/emerging biotech companies developing therapeutics in oncology and other indications to identify opportunities where quantitative pharmacology and PKPD modelling expertise can be applied to derisk their drug development journey.
If you are interested in meeting at BioTrinity London, please contact us through the partnering system or email Hayley directly at hclose@physiomics.co.uk.
We look forward to seeing you there!
Enquiries:
Physiomics plc
Dr Jim Millen, Non-Executive Chairman, +44 (0)1865 784 980
Dr Peter Sargent, Chief Executive Officer, +44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling techniques with cancer biology expertise, to help biotech and pharma companies streamline their drug development journeys. Our approach is to derive insight from all relevant data in order to de-risk decision making and optimise design of pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour technology, the Physiomics team has informed the development of over 100 commercial projects, over 50 targets and 75 drugs. Clients include Merck KGaA, Astellas, Bicycle Therapeutics, Numab Therapeutics & CRUK.